Arvig Deploys Wi-Fi 7 Speeds Network-Wide 
Your Next Customer Isn’t Googling You. They’re Asking AI Senti Bio to Present Preclinical Data for SENTI-202 at the 2022 ASH Annual Meeting
Poster presentation to highlight preclinical data for SENTI-202 which employs Logic Gating gene circuit technology…
Neoleukin Therapeutics Announces Oral Presentation at 64th American Society of Hematology (ASH) Annual Meeting
SEATTLE, Nov. 03, 2022 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company…
Cogent Biosciences Announces Bezuclastinib Presentations at the 64th Annual American Society of Hematology (ASH) Meeting
Company to Host Virtual Investor Event on Monday, December 12 WALTHAM, Mass. and BOULDER, Colo.,…
Affimed Announces Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells and Preclinical AFM28 Data at ASH 2022 Annual Meeting
In 24 patients with CD30-positive lymphoma treated at the highest dose level, the combination treatment…
IGM Biosciences Announces Third Quarter 2022 Financial Results and Provides Corporate Update
– Data from T cell Engager Portfolio for Hematologic Malignancies, Including First Preclinical Data for…
Apellis to Present New Long-Term Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI® (pegcetacoplan) in PNH Patients at 2022 ASH Annual Meeting
Robust improvements in key markers of disease sustained across a broad population of adults with…
Allogene Therapeutics Announces Poster Presentation of Its Phase 1 UNIVERSAL Trial in Multiple Myeloma at the 64th Annual Meeting of the American Society of Hematology
ALLO-715, an Allogeneic BCMA CAR T Candidate Dosed with an ALLO-647 Based Lymphodepletion Regimen, Continues…
Centessa Pharmaceuticals to Present Additional 18-Months of Continued Treatment Data with SerpinPC from Open-Label Extension of Phase 2a Study at 64th ASH Annual Meeting
New efficacy and safety data from 18-months of continued treatment with subcutaneous doses of SerpinPC…
Magenta Therapeutics Reports Third Quarter Financial Results and Recent Program Highlights
– New clinical results from ongoing MGTA-117 Phase 1/2 clinical trial support earlier observations of…
Genmab Announces Multiple Abstracts to be Presented at the 64th Annual Meeting and Exposition of the American Society of Hematology (ASH)
Media Release Copenhagen, Denmark, November 3, 2022 Nineteen abstracts accepted, including multiple presentations on the…
Tessa Therapeutics Announces Three Abstracts Highlighting Data from Autologous and Allogeneic Cell Therapy Programs Accepted for Presentation at 64th ASH Annual Meeting and Exposition
New data from clinical trials of TT11 and TT11X to be featured in two oral…
Magenta Therapeutics to Present Data at the 2022 American Society of Hematology (ASH) Annual Meeting
– Oral presentation of MGTA-117 Phase 1/2 dose escalation clinical trial abstract, with additional clinical…
Sutro Biopharma Announces Oral Presentation at the 64th American Society of Hematology Annual Meeting and Exposition
–Results from compassionate use program highlight promising activity of STRO-002 in children with rare form…
Roche to present data at ASH 2022 showcasing strength of haematology portfolio and expanding into new areas to address more patient needs
Interim data from phase III HAVEN 7 study reinforce Hemlibra’s efficacy and safety in infants…
Step Pharma to Present Promising Data on the Therapeutic Potential of Selective Small Molecule Inhibition of CTPS1 at the 64th American Society of Hematology Annual Meeting
Step Pharma to Present Promising Data on the Therapeutic Potential of Selective Small Molecule Inhibition…
ORIC Pharmaceuticals to Present Preclinical Data on CD73 Inhibitor Program in Multiple Myeloma at the 64th American Society of Hematology (ASH) Annual Meeting
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals,…
Keros Therapeutics to Present at the 64th American Society of Hematology Annual Meeting and Exposition, Including Presenting Data from its Phase 2 Clinical Trials Evaluating KER-050 and KER-047
LEXINGTON, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a…
Kura Oncology Announces Four Abstracts Accepted for Presentation at ASH Annual Meeting
Abstract featuring updated data from KOMET-001 trial of ziftomenib accepted for oral presentation on December…
Nurix Therapeutics Announces Presentations at the 64th American Society of Hematology (ASH) Annual Meeting
Nurix to provide a clinical update from the ongoing Phase 1 trial of NX-2127 in…
Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at the 2022 ASH Annual Meeting
Clinical Presentations to Include Initial Clinical Data of FT576 BCMA-targeted CAR NK Cell Product Candidate…